propranololWhat was measured
Measured, with no finding
601 endpoints
Show what was measuredHide what was measured
Gastrointestinal hemorrhage, pooled risk difference
decreases
Pooled risk differences of gastrointestinal hemorrhage were -18 % [95 % CI, -25 %, -10 %] in all trials
PMID 12918133 · one of two readings recorded this
Gastrointestinal hemorrhage, pooled risk difference
decreases
-11 % [95 % CI, -21 %, -1 %] in primary prevention trials
PMID 12918133 · one of two readings recorded this
Gastrointestinal hemorrhage, pooled risk difference
decreases
-25 % [95 % CI, -39 %, -10 %] in secondary prevention trials
PMID 12918133 · one of two readings recorded this
Total deaths, number of patients
decreases
A total of 440 patients died, 188 in propranolol groups and 252 in control groups
PMID 12918133 · one of two readings recorded this
Total mortality, pooled risk difference
decreases
Pooled risk differences of total death were -7 % [95 % CI, -12 %, -3 %] in all trials
PMID 12918133 · one of two readings recorded this
Total mortality, pooled risk difference
decreases
-9 % [95 % CI, -18 %, -1 %] in primary prevention trials
PMID 12918133 · one of two readings recorded this
Total mortality, pooled risk difference
decreases
-5 % [95 % CI, -9 %, -1 %] in secondary prevention trials
PMID 12918133 · one of two readings recorded this
clinical effectiveness of propranolol versus systemic steroids in airway haemangiomas (35 children), and percentage airway obstruction before and after propranolol (21 patients)
increases, n = 35
Not recorded as a finding: the comparison was against another active treatment
Propranolol treatment outperformed steroids in the vast majority of patients (33 cases, 94%), whereas steroids showed superior outcome only in two cases (6%).
PMID 23093810 · one of two readings recorded this
comparative outcome of propranolol versus systemic steroids in airway haemangiomas (35 children, chi-square); airway obstruction percentage before and after propranolol (paired t-test)
increases, propranolol outperformed steroids in 33 cases (94%), steroids superior in two (6%), n = 35
Not recorded as a finding: the comparison was against another active treatment
Propranolol treatment outperformed steroids in the vast majority of patients (33 cases, 94%), whereas steroids showed superior outcome only in two cases (6%).
PMID 23093810 · one of two readings recorded this
Comparative outcome, propranolol better than systemic steroids
increases, p = 0.001
Propranolol treatment outperformed steroids in the vast majority of patients (33 cases, 94%), whereas steroids showed superior outcome only in two cases (6%). The result was statistically significant (p < 0.001)
PMID 23093810 · one of two readings recorded this
Failure to respond to propranolol
Four children from our study population failed to respond to propranolol treatment (6.5%), and in seven the haemangioma relapsed after discontinuation of treatment (11.5%)
PMID 23093810 · one of two readings recorded this
Mean airway obstruction
decreases, p = 0.001
The mean obstruction before the administration of propranolol was 72%, and after intervention was 20%. The result proved statistically significant (p < 0.001)
PMID 23093810 · one of two readings recorded this
Mean follow-up duration
Treated children were followed up for a mean of 8.4 months
PMID 23093810 · one of two readings recorded this
Mean referral age
The mean referral age for children with airway haemangiomas was 2.4 months (range 0.7-8 months)
PMID 23093810 · one of two readings recorded this
Mean starting age of propranolol treatment
the mean starting age of propranolol treatment 5.1 months (range 0.75-22 months)
PMID 23093810 · one of two readings recorded this
Relapse after discontinuation of propranolol
Four children from our study population failed to respond to propranolol treatment (6.5%), and in seven the haemangioma relapsed after discontinuation of treatment (11.5%)
PMID 23093810 · one of two readings recorded this
Subsequent recall of negatively valenced emotional material after pre-consolidation dosing
decreases, n = 259
propranolol given before memory consolidation reduced subsequent recall for negatively valenced stories, pictures and word lists (Hedges g = 0.44, 95% confidence interval [CI] 0.14-0.74)
PMID 23182304 · one of two readings recorded this
Subsequent recall of negatively valenced emotional words and cue-elicited fear responses after pre-reconsolidation dosing
decreases, n = 308
Propranolol before reconsolidation also reduced subsequent recall for negatively valenced emotional words and the expression of cue-elicited fear responses (Hedges g = 0.56, 95% CI 0.13-1.00)
PMID 23182304 · one of two readings recorded this
subsequent recall of negatively valenced stories, pictures and word lists after propranolol before consolidation; cue-elicited fear responses after reconsolidation; Hedges g
decreases, Hedges g = 0.44, 95% confidence interval [CI] 0.14-0.74
Not recorded as a finding: this platform holds no node for the endpoint
Compared with placebo, propranolol given before memory consolidation reduced subsequent recall for negatively valenced stories, pictures and word lists (Hedges g = 0.44, 95% confidence interval [CI] 0.14-0.74).
PMID 23182304 · one of two readings recorded this
Efficacy in infantile haemangiomas, pooled
increases, p = 0.001
The efficacy of propranolol was greater than other therapies in treating IHs (OR = 9.67, 95% CI 6.62, 14.12, P < 0.001)
PMID 24033819 · one of two readings recorded this
Efficacy in infantile haemangiomas
increases, p = 0.02
laser treatment (OR = 9.00, 95% CI 1.42, 57.12, P = 0.020)
PMID 24033819 · one of two readings recorded this
Efficacy in infantile haemangiomas
increases, p = 0.001
propranolol was a more effective therapy when compared with steroids (OR = 9.67, 95% CI 6.61, 14.15, P < 0.001)
PMID 24033819 · one of two readings recorded this
Efficacy in infantile haemangiomas
increases, p = 0.003
vincristine (OR = 9.00, 95% CI 2.15, 37.66, P = 0.003)
PMID 24033819 · one of two readings recorded this
Efficacy in infantile haemangiomas
increases, p = 0.001
cutaneous IHs (OR = 24.95, 95% CI 9.48, 65.64, P < 0.001)
PMID 24033819 · one of two readings recorded this
Efficacy in infantile haemangiomas
increases, p = 0.001
infantile airway haemangiomas (OR = 20.91, 95% CI 7.81, 55.96, P < 0.001)
PMID 24033819 · one of two readings recorded this
Efficacy in infantile haemangiomas
increases, p = 0.033
infantile hepatic haemangiomas (OR = 9.89, 95% CI 1.20, 81.54, P = 0.033)
PMID 24033819 · one of two readings recorded this
Efficacy in infantile haemangiomas
increases, p = 0.001
peri-ocular IHs (OR = 9.39, 95% CI 3.88, 22.71, P < 0.001)
PMID 24033819 · one of two readings recorded this
efficacy of propranolol in infantile haemangiomas, pooled odds ratio against other therapies (steroids, vincristine, laser)
increases, OR = 9.67, 95% CI 6.62, 14.12
Not recorded as a finding: the comparison was against another active treatment
The efficacy of propranolol was greater than other therapies in treating IHs (OR = 9.67, 95% CI 6.62, 14.12, P < 0.001).
PMID 24033819 · one of two readings recorded this
efficacy of propranolol in infantile haemangiomas versus other therapies (steroids, vincristine, laser), pooled odds ratio
increases, OR = 9.67, 95% CI 6.62, 14.12
Not recorded as a finding: the comparison was against another active treatment
The efficacy of propranolol was greater than other therapies in treating IHs (OR = 9.67, 95% CI 6.62, 14.12, P < 0.001).
PMID 24033819 · one of two readings recorded this
Effectiveness (response) in infantile hemangiomas, pooled
The pooled OR for effectiveness was 0.55 (95%CI, 0.43–0.67
PMID 26375455 · one of two readings recorded this
Effectiveness (response) in infantile hemangiomas, pooled
the OR was 0.56 (95%CI, 0.50–0.61
PMID 26375455 · one of two readings recorded this
Effectiveness (response) in infantile hemangiomas, pooled
The pooled odd ratio (OR) for effectiveness was 0.92 (95% CI, 0.89–0.95)
PMID 26375455 · one of two readings recorded this
Effectiveness (response) in infantile hemangiomas, pooled
0.55 (95%CI, 0.28–0.81
PMID 26375455 · one of two readings recorded this
Effectiveness (response) in infantile hemangiomas, pooled
In the pooled analysis, the OR was 0.68 (95%CI, 0.59–0.76
PMID 26375455 · one of two readings recorded this
Effectiveness (response) in infantile hemangiomas
< 2 | 4 | 0.90 (0.79, 1.00) | 89 | <0.001
PMID 26375455 · one of two readings recorded this
Effectiveness (response) in infantile hemangiomas
Asian | 9 | 0.96 (0.93, 0.99) | 85.4 | <0.001
PMID 26375455 · one of two readings recorded this
Effectiveness (response) in infantile hemangiomas
Europe | 14 | 0.91 (0.86, 0.96) | 89.3 | <0.001
PMID 26375455 · one of two readings recorded this
Effectiveness (response) in infantile hemangiomas
United States | 7 | 0.86 (0.77, 0.95) | 86.1 | <0.001
PMID 26375455 · one of two readings recorded this
Effectiveness (response) in infantile hemangiomas
Head and Neck | 8 | 0.89 (0.81, 0.97) | 88.1 | <0.001
PMID 26375455 · one of two readings recorded this
Effectiveness (response) in infantile hemangiomas
Head, Neck and others | 17 | 0.88 (0.84, 0.93) | 90.4 | <0.001
PMID 26375455 · one of two readings recorded this
Effectiveness (response) in infantile hemangiomas
No | 15 | 0.95 (0.91, 0.98) | 88 | <0.001
PMID 26375455 · one of two readings recorded this
Effectiveness (response) in infantile hemangiomas
Yes | 15 | 0.88 (0.83, 0.93) | 86.5 | <0.001
PMID 26375455 · one of two readings recorded this
HAM-A after 2-6 weeks of treatment (meta-analysis III), sensitivity analysis excluding study at high risk of selective reporting
no effect, p = 0.16
two trials, 63 participants in total; MD = 5.76 [–2.27 to 13.79], Z = 1.41, p = 0.16
PMID 26487439 · one of two readings recorded this
HAM-A after 2-6 weeks of treatment (meta-analysis III)
no effect, p = 0.32
No significant overall effect was found (mean difference = −2.20, 95%-CI [–8.49; 4.09], Z = 0.99, p = 0.32)
PMID 26487439 · one of two readings recorded this
HAM-A after 2 weeks of treatment (meta-analysis II)
no effect, p = 0.78
No significant difference was found between propranolol and benzodiazepines (mean difference = 2.81, 95%-CI [–16.87; 22.49], Z = 0.28, p = 0.78)
PMID 26487439 · one of two readings recorded this
HAM-A after 6 weeks of treatment (meta-analysis IV)
no effect, p = 0.8
No significant difference was found between propranolol and alprazolam (mean difference = 0.51, 95%-CI [–3.39; 4.42], Z = 0.26, p = 0.80)
PMID 26487439 · one of two readings recorded this
Hamilton Anxiety Rating Scale (HAM-A) after 2 weeks of treatment, propranolol versus benzodiazepines in panic disorder, pooled weighted mean difference
no effect, mean difference = 2.81, 95%-CI [–16.87; 22.49], p = 0.78, n = 50
Not recorded as a finding: the comparison was against another active treatment
No significant difference was found between propranolol and benzodiazepines (mean difference = 2.81, 95%-CI [–16.87; 22.49], Z = 0.28, p = 0.78).
PMID 26487439 · one of two readings recorded this
number of panic attacks after 2 weeks, and HAM-A anxiety scores at 2 to 6 weeks, pooled weighted mean difference of oral propranolol versus benzodiazepines (alprazolam, diazepam) in panic disorder with or without agoraphobia
no effect, p = 0.43
Not recorded as a finding: the comparison was against another active treatment
No significant difference was found between propranolol and benzodiazepines (mean difference = 1.58, 95%-CI [–2.33; 5.50], Z = 0.79, p = 0.43).
PMID 26487439 · one of two readings recorded this
number of panic attacks after 2 weeks of treatment (meta-analysis I)
no effect, p = 0.43
No significant difference was found between propranolol and benzodiazepines (mean difference = 1.58, 95%-CI [–2.33; 5.50], Z = 0.79, p = 0.43)
PMID 26487439 · one of two readings recorded this
physiologic responding during mental imagery of traumatic event, 1 week later
decreases, p = 0.007
statistically reduced physiological responding (reduced heart rate and skin conductance) during imaginary exposure 1 week later (F(3,15) = 5.1; p = 0.007, η2 = 0.49)
PMID 26487439 · one of two readings recorded this
self-reported anxiety at injection
decreases, p = 0.033
self-reported anxiety at injection: 5.5 (2.75) versus 7.45 (2.0), p = 0.033, one-tailed
PMID 26487439 · one of two readings recorded this
self-reported trait anxiety
no effect
One 3-week crossover trial with specific (animal type: snake or spider) phobia subjects by reported no significant effects of propranolol on self-reported trait anxiety
PMID 26487439 · one of two readings recorded this
state and trait anxiety at 6 months follow-up after social skills training
no effect
It reported absence of statistically significant effects of propranolol on state and trait anxiety 6 months follow-up after a social skills training
PMID 26487439 · one of two readings recorded this
all-cause mortality
increases, p = 0.01
<1 year of prescriptionsc | 1012 | 4512 | 17,074 | 1.23 (0.98, 1.55) | 0.08 | 89% (<0.01) | 1.22 (1.04, 1.43) | 0.02 | 75% (<0.01) | 1.19 (1.04, 1.36) | 0.01 | 54% (0.03)
PMID 27906047 · one of two readings recorded this
all-cause mortality
no effect, p = 0.16
<1 year of prescriptionsc | 548 | 3099 | 10,977 | 1.01 (0.78, 1.32) | 0.92 | 85% (<0.01) | 1.20 (0.93, 1.53) | 0.16 | 83% (<0.01) | 1.15 (0.95, 1.39) | 0.16 | 62% (0.01)
PMID 27906047 · one of two readings recorded this
all-cause mortality
increases, p = 0.001
Any beta-blocker | 25,472 | 133,251 | 570,968 | 1.57 (1.41, 1.75) | <0.001 | 92% (<0.001) | 1.12 (1.05, 1.20) | <0.001 | 65% (0.006)
PMID 27906047 · one of two readings recorded this
all-cause mortality
increases, p = 0.02
Non-selective bb userb | 1732 | 7931 | 27,624 | 1.34 (1.14, 1.58) | 0.001 | 87% (<0.01) | 1.22 (1.09, 1.36) | 0.001 | 70% (<0.01) | 1.16 (1.02, 1.32) | 0.02 | 71% (<0.01)
PMID 27906047 · one of two readings recorded this
all-cause mortality
increases, p = 0.001
Non-selective beta-blocker | 31,556 | 139,760 | 664,448 | 1.30 (1.14, 1.49) | <0.001 | 80% (<0.001) | 1.13 (1.06, 1.21) | <0.001 | 27% (0.21)
PMID 27906047 · one of two readings recorded this
all-cause mortality
no effect, p = 0.06
Non-selective beta-blocker | 25,487 | 133,251 | 571,213 | 1.35 (1.17, 1.55) | <0.001 | 78% (<0.001) | 1.14 (0.99, 1.30) | 0.06 | 68% (0.003)
PMID 27906047 · one of two readings recorded this
all-cause mortality
no effect
once this was removed the pooled estimate was attenuated slightly (fully adjusted HR = 1.03, 95% CI, 0.88, 1.20)
PMID 27906047 · one of two readings recorded this
all-cause mortality
no effect, p = 0.27
Propranolol userb | 818 | 4746 | 16,202 | 1.04 (0.86, 1.27) | 0.68 | 82% (<0.01) | 1.13 (0.93, 1.37) | 0.21 | 81% (<0.01) | 1.09 (0.93, 1.28) | 0.27 | 65% (0.006)
PMID 27906047 · one of two readings recorded this
all-cause mortality
no effect, p = 0.68
Propranolol userb | 818 | 4746 | 16,202 | 1.04 (0.86, 1.27) | 0.68 | 82% (<0.01) | 1.13 (0.93, 1.37) | 0.21 | 81% (<0.01) | 1.09 (0.93, 1.28) | 0.27 | 65% (0.006)
PMID 27906047 · one of two readings recorded this
all-cause mortality
no effect, p = 0.68
Propranolol | 31,556 | 139,760 | 664,448 | 0.97 (0.86, 1.09) | 0.60 | 44% (0.09) | 1.02 (0.94, 1.10) | 0.68 | 0% (0.54)
PMID 27906047 · one of two readings recorded this
all-cause mortality
no effect, p = 0.62
Propranolol | 25,487 | 133,251 | 571,213 | 1.02 (0.89, 1.16) | 0.82 | 48% (0.06) | 1.04 (0.89, 1.21) | 0.62 | 48% (0.06)
PMID 27906047 · one of two readings recorded this
all-cause mortality
increases, p = 0.02
Propranolol in stages 1–3c | 17,219 | 96,097 | 382,1512 | 1.07 (0.93, 1.24) | 0.32 | 29% (0.21) | 1.13 (1.02, 1.24) | 0.02 | 0% (0.46)
PMID 27906047 · one of two readings recorded this
aromatase inhibitor use in the year after diagnosis
increases
There was a higher use of hormone antagonists (tamoxifen 39% versus 30% and aromatase inhibitors 26% versus 23%, respectively) in propranolol users versus non-users
PMID 27906047 · one of two readings recorded this
breast cancer-specific mortality, fully adjusted pooled HR
no effect, HR = 0.94, 95% CI, 0.77, 1.16
Not recorded as a finding: No outcome node for cancer-specific mortality (only all-cause and cardiovascular mortality exist).
Overall, there was little difference in breast cancer-specific mortality or all-cause mortality in propranolol users compared with non-users after diagnosis (fully adjusted HR = 0.94, 95% CI, 0.77, 1.16 and HR = 1.09, 95% CI, 0.93, 1.28, respectively).
PMID 27906047 · one of two readings recorded this
breast cancer-specific mortality, pooled fully adjusted hazard ratio, propranolol use after diagnosis
no effect, HR = 0.94, 95% CI 0.77-1.16
Not recorded as a finding: No outcome node for cancer-specific mortality (cardiovascular-mortality node is cause-specific to CVD only)
Overall, there was little difference in breast cancer-specific mortality or all-cause mortality in propranolol users compared with non-users after diagnosis (fully adjusted HR = 0.94, 95% CI, 0.77, 1.16 and HR = 1.09, 95% CI, 0.93, 1.28, respectively).
PMID 27906047 · one of two readings recorded this
breast cancer-specific mortality
no effect, p = 0.36
<1 year of prescriptionsc | 145 | 1466 | 4555 | 1.13 (0.93, 1.37) | 0.22 | 22% (0.27) | 1.16 (0.99, 1.37) | 0.07 | 0% (0.55) | 1.10 (0.90, 1.34) | 0.36 | 0% (0.70)
PMID 27906047 · one of two readings recorded this
breast cancer-specific mortality
no effect, p = 0.96
<1 year of prescriptionsc | 88 | 1217 | 3703 | 1.00 (0.79, 1.26) | 0.98 | 22% (0.27) | 1.09 (0.88, 1.35) | 0.42 | 9% (0.35) | 1.01 (0.80, 1.27) | 0.96 | 0% (0.62)
PMID 27906047 · one of two readings recorded this
breast cancer-specific mortality
no effect, p = 0.1
Any beta-blocker | 5419 | 55,252 | 181,714 | 1.25 (1.11, 1.40) | <0.001 | 63% (0.03) | 1.07 (0.99, 1.16) | 0.10 | 0% (0.82)
PMID 27906047 · one of two readings recorded this
breast cancer-specific mortality
no effect, p = 0.9
Non-selective bb userb | 204 | 2349 | 6706 | 1.08 (0.94, 1.24) | 0.31 | 0% (0.51) | 1.07 (0.93, 1.23) | 0.37 | 0% (0.92) | 1.01 (0.85, 1.20) | 0.90 | 0% (0.47)
PMID 27906047 · one of two readings recorded this
breast cancer-specific mortality
no effect, p = 0.45
Non-selective beta-blocker | 6883 | 53,870 | 215,978 | 1.09 (0.95, 1.25) | 0.22 | 0% (0.47) | 1.05 (0.92, 1.21) | 0.45 | 0% (0.68)
PMID 27906047 · one of two readings recorded this
breast cancer-specific mortality
no effect, p = 0.35
Non-selective beta-blocker | 5426 | 55,252 | 181,959 | 1.10 (0.87, 1.39) | 0.43 | 51% (0.09) | 1.15 (0.85, 1.56) | 0.35 | 60% (0.04)
PMID 27906047 · one of two readings recorded this
breast cancer-specific mortality
no effect, p = 0.56
Propranolol userb | 128 | 1770 | 4989 | 0.92 (0.77, 1.10) | 0.36 | 0% (0.75) | 0.97 (0.82, 1.16) | 0.77 | 0% (0.84) | 0.94 (0.77, 1.16) | 0.56 | 0% (0.56)
PMID 27906047 · one of two readings recorded this
breast cancer-specific mortality
no effect, p = 0.36
Propranolol userb | 128 | 1770 | 4989 | 0.92 (0.77, 1.10) | 0.36 | 0% (0.75) | 0.97 (0.82, 1.16) | 0.77 | 0% (0.84) | 0.94 (0.77, 1.16) | 0.56 | 0% (0.56)
PMID 27906047 · one of two readings recorded this
breast cancer-specific mortality
no effect, p = 0.78
Propranolol | 6883 | 53,870 | 215,978 | 0.97 (0.82, 1.15) | 0.73 | 0% (0.51) | 1.03 (0.86, 1.22) | 0.78 | 3% (0.39)
PMID 27906047 · one of two readings recorded this
breast cancer-specific mortality
no effect, p = 0.72
Propranolol | 5426 | 55,252 | 181,959 | 0.94 (0.72, 1.21) | 0.61 | 35% (0.19) | 1.07 (0.72, 1.60) | 0.72 | 65% (0.02)
PMID 27906047 · one of two readings recorded this
breast cancer-specific mortality
no effect, p = 0.62
Propranolol in stages 1–3 | 3389 | 44,376 | 112,450 | 1.02 (0.82, 1.26) | 0.88 | 0% (0.84) | 1.06 (0.85, 1.33) | 0.62 | 0% (0.60)
PMID 27906047 · one of two readings recorded this
tamoxifen use in the year after diagnosis
increases
There was a higher use of hormone antagonists (tamoxifen 39% versus 30% and aromatase inhibitors 26% versus 23%, respectively) in propranolol users versus non-users
PMID 27906047 · one of two readings recorded this
blood transfused
decreases
propranolol was associated with a lower amount of transfused blood (measured in milliliters) in adults (MD −185.64 [95% CI −331.06 to −40.43])
PMID 28265298 · one of two readings recorded this
blood transfused
no effect
no differences in mortality (RD −0.12 [95% CI −0.32 to 0.07]) and quantity of blood transfused (MD −405 [95% CI −1343.48 to 533.48])
PMID 28265298 · one of two readings recorded this
heart rate
decreases
Propranolol was associated with lower values of heart rate (beats per minute) when compared to usual care (MD −26.85 [95% CI −39.95 to −13.75])
PMID 28265298 · one of two readings recorded this
heart rate
decreases
this was consistent in adults (MD −32.54 [95% CI −38.45 to −26.63]) and children (MD −19.0 [95% CI −31.12 to −6.88])
PMID 28265298 · one of two readings recorded this
heart rate
decreases
this was consistent in adults (MD −32.54 [95% CI −38.45 to −26.63]) and children (MD −19.0 [95% CI −31.12 to −6.88])
PMID 28265298 · one of two readings recorded this
hospital length of stay, pooled mean difference in days
MD -0.37 [-4.52 to 3.78]
Not recorded as a finding: Sentence uses a one-sided negation ('did not shorten') and continues with a qualifier about subgroups; not recordable as no_effect
When assessing the length of hospital stay, propranolol did not shorten the overall number of days of hospitalization when compared to usual care or placebo (MD −0.37 [−4.52 to 3.78]) but this was not sustained when assessing sub-groups.
PMID 28265298 · one of two readings recorded this
length of hospital stay
no effect
propranolol did not shorten the overall number of days of hospitalization when compared to usual care or placebo (MD −0.37 [−4.52 to 3.78])
PMID 28265298 · one of two readings recorded this
length of hospital stay
decreases
propranolol was associated with a lower length of hospital stay in children (MD −2.0 [CI 95% −2.51 to −1.49]) and adults (MD −6.54 [95% CI −10.19 to −2.89])
PMID 28265298 · one of two readings recorded this
length of hospital stay
decreases
the use of propranolol was associated with a lower length of hospital stay in adults (MD −6.59 [95% CI −10.18 to −3.0])
PMID 28265298 · one of two readings recorded this
length of hospital stay
decreases
propranolol was associated with a lower length of hospital stay in children (MD −2.0 [CI 95% −2.51 to −1.49]) and adults (MD −6.54 [95% CI −10.19 to −2.89])
PMID 28265298 · one of two readings recorded this
length of hospital stay
no effect
a fact that did not occur in children (MD 2.30 [95% CI −3.36 to 7.96])
PMID 28265298 · one of two readings recorded this
mortality
no effect
There were no significant differences between propranolol and placebo/usual care with respect to mortality (RD −0.02 [95% CI −0.06 to 0.02])
PMID 28265298 · one of two readings recorded this
mortality
no effect
no differences were found in the sub-group analysis when assessing this outcome in children (RD −0.02 [95% CI −0.06 to 0.02]) and adults (RD −0.05 [95% CI −0.17 to 0.07])
PMID 28265298 · one of two readings recorded this
mortality
no effect
no differences were found in the sub-group analysis when assessing this outcome in children (RD −0.02 [95% CI −0.06 to 0.02]) and adults (RD −0.05 [95% CI −0.17 to 0.07])
PMID 28265298 · one of two readings recorded this
mortality
no effect
no differences in mortality (RD −0.12 [95% CI −0.32 to 0.07]) and quantity of blood transfused (MD −405 [95% CI −1343.48 to 533.48])
PMID 28265298 · one of two readings recorded this
overall hospital length of stay, pooled mean difference in days
MD −0.37 [−4.52 to 3.78]
Not recorded as a finding: Sentence 'propranolol did not shorten the overall number of days' is a one-sided negation and continues into a subgroup qualifier; node hospital-length-of-stay exists but no clean two-sided sentence.
When assessing the length of hospital stay, propranolol did not shorten the overall number of days of hospitalization when compared to usual care or placebo (MD −0.37 [−4.52 to 3.78]) but this was not sustained when assessing sub-groups.
PMID 28265298 · one of two readings recorded this
sepsis occurrence in severely burned patients, pooled risk difference
no effect, RD -0.03 [95% CI -0.09 to 0.04]
Not recorded as a finding: No outcome node for sepsis; infectious-complication-rate requires each source's own infectious complication case definition and sepsis is a narrower construct
Similarly, no significant differences were found when assessing overall occurrence of sepsis (RD −0.03 [95% CI −0.09 to 0.04]) with no differences in children (RD −0.03 [95% CI −0.09 to 0.04]) and adults (RD −0.04 [95% CI −0.24 to 0.15]).
PMID 28265298 · one of two readings recorded this
sepsis
no effect
no significant differences were found when assessing overall occurrence of sepsis (RD −0.03 [95% CI −0.09 to 0.04])
PMID 28265298 · one of two readings recorded this
sepsis
no effect
with no differences in children (RD −0.03 [95% CI −0.09 to 0.04]) and adults (RD −0.04 [95% CI −0.24 to 0.15])
PMID 28265298 · one of two readings recorded this
sepsis
no effect
with no differences in children (RD −0.03 [95% CI −0.09 to 0.04]) and adults (RD −0.04 [95% CI −0.24 to 0.15])
PMID 28265298 · one of two readings recorded this
volume of blood transfused in mL, adults only
decreases, MD -185.64 [95% CI -331.06 to -40.43]
Not recorded as a finding: No outcome node for transfusion requirement; estimate is adults-only subgroup
With respect to blood transfused, propranolol was associated with a lower amount of transfused blood (measured in milliliters) in adults (MD −185.64 [95% CI −331.06 to −40.43]).
PMID 28265298 · one of two readings recorded this
memory valence moderator, between-group difference
no effect, p = 0.44
although the between-group difference was not statistically significant (Q 1 = 0.587, p = 0.44)
PMID 35361699 · one of two readings recorded this
publication bias, Egger test
p = 0.31
The result of the Egger test was not statistically significant (p = 0.31), suggesting little risk of publication bias
PMID 35361699 · one of two readings recorded this
publication bias, Egger test
p = 0.023
However, the result of the Egger test was statistically significant (p = 0.023), suggesting a risk of publication bias (i.e., small studies reporting large effects)
PMID 35361699 · one of two readings recorded this
recall of aversive/emotional material and cue-elicited conditioned physiologic responses after memory reactivation under propranolol (healthy adults); psychiatric symptom severity and cue-induced reactivity (clinical samples); pooled Hedges g
decreases, g = −0.51, 95 % CI −0.84 to −0.19, p = 0.002
Not recorded as a finding: this platform holds no node for the endpoint
As shown in Figure 2, propranolol-treated participants (n = 242) remembered less aversive material than placebo-treated participants (n = 236; g = −0.51, 95 % CI −0.84 to −0.19; p = 0.002).
PMID 35361699 · one of two readings recorded this
recall of aversive emotional material and cue-elicited conditioned responses after memory reactivation under propranolol versus placebo in healthy adults (pooled Hedges g); symptom severity and cue-induced physiologic reactivity in clinical samples (PTSD, addiction, phobia)
decreases, g = -0.51, 95% CI -0.84 to -0.19 (healthy adults, recall of aversive material), p = 0.002, n = 478
Not recorded as a finding: this platform holds no node for the endpoint
As shown in Figure 2, propranolol-treated participants (n = 242) remembered less aversive material than placebo-treated participants (n = 236; g = −0.51, 95 % CI −0.84 to −0.19; p = 0.002).
PMID 35361699 · one of two readings recorded this
recall of aversive material (memory reconsolidation impairment)
decreases, p = 0.002
propranolol-treated participants (n = 242) remembered less aversive material than placebo-treated participants (n = 236; g = −0.51, 95 % CI −0.84 to −0.19; p = 0.002)
PMID 35361699 · one of two readings recorded this
symptom severity and cue-induced physiologic reactivity (memory reconsolidation impairment)
decreases, p = 0.01
The overall effect size was moderate, and the difference was significant in favour of propranolol (g = −0.42, 95 % CI −0.74 to −0.10; p = 0.010)
PMID 35361699 · one of two readings recorded this
symptom severity and cue-induced physiologic reactivity (memory reconsolidation impairment)
no effect, p = 0.29
The overall effect size was larger for studies that involved aversive memories (e.g., trauma or phobia; g = −0.53, p = 0.016) than for those involving appetitive memories (e.g., drug-related; g = −0.27, p = 0.29)
PMID 35361699 · one of two readings recorded this
symptom severity and cue-induced physiologic reactivity (memory reconsolidation impairment)
decreases, p = 0.016
The overall effect size was larger for studies that involved aversive memories (e.g., trauma or phobia; g = −0.53, p = 0.016) than for those involving appetitive memories (e.g., drug-related; g = −0.27, p = 0.29)
PMID 35361699 · one of two readings recorded this
baseline FTM Part A (tremor severity)
no effect, p = 0.576, n = 38
FTM score Part A | 7.15 ± 2.92 | 6.72 ± 3.14 |.576
PMID 36806734 · one of two readings recorded this
baseline FTM Part B (specific motor tasks)
no effect, p = 0.298, n = 38
FTM score Part B | 11.75 ± 5.66 | 14.06 ± 6.60 |.298
PMID 36806734 · one of two readings recorded this
baseline FTM Part C (functional disability)
no effect, p = 0.906, n = 38
FTM score Part C | 9.75 ± 3.61 | 9.83 ± 4.40 |.906
PMID 36806734 · one of two readings recorded this
baseline FTM total score
no effect, p = 0.558, n = 38
FTM total score | 28.65 ± 10.18 | 30.61 ± 12.97 |.558
PMID 36806734 · one of two readings recorded this
Fahn-Tolosa-Marin (FTM) clinical tremor scale total score, 1-Hz cerebellar rTMS versus oral propranolol (30 to 90 mg/day) in essential tremor
no effect, treatment difference rTMS minus propranolol not significant on days 5, 10 and 30
Not recorded as a finding: the comparison was against another active treatment
Comparisons between the two groups indicated that for the FTM total score, the treatment difference (rTMS effect‐propranolol effect) was not significant on day 5 (p =.198), day 10 (p =.147), or day 30 (p =.639).
PMID 36806734 · one of two readings recorded this
Fahn-Tolosa-Marin (FTM) tremor rating scale total score and Parts A, B, C at days 5, 10 and 30 in essential tremor, oral propranolol 30 to 90 mg/day versus 1-Hz cerebellar rTMS
no effect
Not recorded as a finding: the comparison was against another active treatment
Comparisons between the two groups indicated that for the FTM total score, the treatment difference (rTMS effect‐propranolol effect) was not significant on day 5 (p =.198), day 10 (p =.147), or day 30 (p =.639).
PMID 36806734 · one of two readings recorded this
FTM Part A (tremor severity), between-group treatment difference
no effect, p = 0.375, n = 38
tremor severity (day 5 [p =.836], day 10 [p =.375], and day 30 [p =.535])
PMID 36806734 · one of two readings recorded this
FTM Part A (tremor severity), between-group treatment difference
no effect, p = 0.535, n = 38
tremor severity (day 5 [p =.836], day 10 [p =.375], and day 30 [p =.535])
PMID 36806734 · one of two readings recorded this
FTM Part A (tremor severity), between-group treatment difference
no effect, p = 0.836, n = 38
tremor severity (day 5 [p =.836], day 10 [p =.375], and day 30 [p =.535])
PMID 36806734 · one of two readings recorded this
FTM Part A (tremor severity), change from baseline test
no effect, p = 0.279, n = 18
tremor severity (day 5 [p =.641], day 10 [p =.279]), specific motor tasks (day 5 [p =.645], day 10 [p =.128]), functional disability (day 5 [p =.823], day 10 [p =.301]), and FTM Total score (day 5 [p =.669], day 10 [p =.189])
PMID 36806734 · one of two readings recorded this
FTM Part A (tremor severity), change from baseline test
decreases, p = 0.024, n = 18
tremor severity (p =.024), specific motor tasks (p =.013), functional disability (p =.026), and FTM total score (p =.012) were significantly reduced compared with baseline
PMID 36806734 · one of two readings recorded this
FTM Part A (tremor severity), change from baseline test
no effect, p = 0.641, n = 18
tremor severity (day 5 [p =.641], day 10 [p =.279]), specific motor tasks (day 5 [p =.645], day 10 [p =.128]), functional disability (day 5 [p =.823], day 10 [p =.301]), and FTM Total score (day 5 [p =.669], day 10 [p =.189])
PMID 36806734 · one of two readings recorded this
FTM Part A (tremor severity), change from baseline test
decreases, p = 0.006, n = 20
tremor severity (p =.006), specific motor tasks (p =.034), and FTM total score (p =.010) were significantly reduced on day 10 after rTMS
PMID 36806734 · one of two readings recorded this
FTM Part A (tremor severity), change from baseline test
decreases, p = 0.011, n = 20
persisted until day 30 (tremor severity [p =.011], specific motor tasks [p =.039], and FTM total score [p =.013])
PMID 36806734 · one of two readings recorded this
FTM Part A (tremor severity), change from baseline test
no effect, p = 0.242, n = 20
FTM score Part A, tremor severity (p =.242); FTM score Part B, specific motor tasks (p =.197); FTM score Part C, functional disability (p =.549); and FTM total score (p =.155) on day 5 compared with baseline
PMID 36806734 · one of two readings recorded this
FTM Part A (tremor severity), mean ± SD
no effect, n = 18
FTM Part A | 6.72 ± 3.14 | 6.33 ± 3.07 | 5.67 ± 2.95 | 4.50 ± 2.26
PMID 36806734 · one of two readings recorded this
FTM Part A (tremor severity), mean ± SD
decreases, n = 18
FTM Part A | 6.72 ± 3.14 | 6.33 ± 3.07 | 5.67 ± 2.95 | 4.50 ± 2.26
PMID 36806734 · one of two readings recorded this
FTM Part A (tremor severity), mean ± SD
no effect, n = 18
FTM Part A | 6.72 ± 3.14 | 6.33 ± 3.07 | 5.67 ± 2.95 | 4.50 ± 2.26
PMID 36806734 · one of two readings recorded this
FTM Part A (tremor severity), mean ± SD
decreases, n = 20
FTM Part A | 7.15 ± 2.92 | 5.95 ± 2.44 | 4.55 ± 1.99 | 4.70 ± 2.11
PMID 36806734 · one of two readings recorded this
FTM Part A (tremor severity), mean ± SD
decreases, n = 20
FTM Part A | 7.15 ± 2.92 | 5.95 ± 2.44 | 4.55 ± 1.99 | 4.70 ± 2.11
PMID 36806734 · one of two readings recorded this
FTM Part A (tremor severity), mean ± SD
decreases, n = 20
FTM Part A | 7.15 ± 2.92 | 5.95 ± 2.44 | 4.55 ± 1.99 | 4.70 ± 2.11
PMID 36806734 · one of two readings recorded this
FTM Part B (specific motor tasks), between-group treatment difference
no effect, p = 0.12, n = 38
performance of motor tasks (day 5 [p =.127], day 10 [p =.120], and day 30 [p =.736])
PMID 36806734 · one of two readings recorded this
FTM Part B (specific motor tasks), between-group treatment difference
no effect, p = 0.736, n = 38
performance of motor tasks (day 5 [p =.127], day 10 [p =.120], and day 30 [p =.736])
PMID 36806734 · one of two readings recorded this
FTM Part B (specific motor tasks), between-group treatment difference
no effect, p = 0.127, n = 38
performance of motor tasks (day 5 [p =.127], day 10 [p =.120], and day 30 [p =.736])
PMID 36806734 · one of two readings recorded this
FTM Part B (specific motor tasks), change from baseline test
no effect, p = 0.128, n = 18
tremor severity (day 5 [p =.641], day 10 [p =.279]), specific motor tasks (day 5 [p =.645], day 10 [p =.128]), functional disability (day 5 [p =.823], day 10 [p =.301]), and FTM Total score (day 5 [p =.669], day 10 [p =.189])
PMID 36806734 · one of two readings recorded this
FTM Part B (specific motor tasks), change from baseline test
decreases, p = 0.013, n = 18
tremor severity (p =.024), specific motor tasks (p =.013), functional disability (p =.026), and FTM total score (p =.012) were significantly reduced compared with baseline
PMID 36806734 · one of two readings recorded this
FTM Part B (specific motor tasks), change from baseline test
no effect, p = 0.645, n = 18
tremor severity (day 5 [p =.641], day 10 [p =.279]), specific motor tasks (day 5 [p =.645], day 10 [p =.128]), functional disability (day 5 [p =.823], day 10 [p =.301]), and FTM Total score (day 5 [p =.669], day 10 [p =.189])
PMID 36806734 · one of two readings recorded this
FTM Part B (specific motor tasks), change from baseline test
decreases, p = 0.034, n = 20
tremor severity (p =.006), specific motor tasks (p =.034), and FTM total score (p =.010) were significantly reduced on day 10 after rTMS
PMID 36806734 · one of two readings recorded this
FTM Part B (specific motor tasks), change from baseline test
decreases, p = 0.039, n = 20
persisted until day 30 (tremor severity [p =.011], specific motor tasks [p =.039], and FTM total score [p =.013])
PMID 36806734 · one of two readings recorded this
FTM Part B (specific motor tasks), change from baseline test
no effect, p = 0.197, n = 20
FTM score Part A, tremor severity (p =.242); FTM score Part B, specific motor tasks (p =.197); FTM score Part C, functional disability (p =.549); and FTM total score (p =.155) on day 5 compared with baseline
PMID 36806734 · one of two readings recorded this
FTM Part B (specific motor tasks), mean ± SD
no effect, n = 18
FTM Part B | 14.06 ± 6.60 | 13.33 ± 6.58 | 11.39 ± 5.64 | 9.00 ± 5.29
PMID 36806734 · one of two readings recorded this
FTM Part B (specific motor tasks), mean ± SD
decreases, n = 18
FTM Part B | 14.06 ± 6.60 | 13.33 ± 6.58 | 11.39 ± 5.64 | 9.00 ± 5.29
PMID 36806734 · one of two readings recorded this
FTM Part B (specific motor tasks), mean ± SD
no effect, n = 18
FTM Part B | 14.06 ± 6.60 | 13.33 ± 6.58 | 11.39 ± 5.64 | 9.00 ± 5.29
PMID 36806734 · one of two readings recorded this
FTM Part B (specific motor tasks), mean ± SD
decreases, n = 20
FTM Part B | 11.75 ± 5.66 | 10.20 ± 5.15 | 8.40 ± 4.77 | 8.60 ± 4.73
PMID 36806734 · one of two readings recorded this
FTM Part B (specific motor tasks), mean ± SD
decreases, n = 20
FTM Part B | 11.75 ± 5.66 | 10.20 ± 5.15 | 8.40 ± 4.77 | 8.60 ± 4.73
PMID 36806734 · one of two readings recorded this
FTM Part B (specific motor tasks), mean ± SD
decreases, n = 20
FTM Part B | 11.75 ± 5.66 | 10.20 ± 5.15 | 8.40 ± 4.77 | 8.60 ± 4.73
PMID 36806734 · one of two readings recorded this
FTM Part C (functional disability), between-group treatment difference
no effect, p = 0.331, n = 38
functional disability (day 5 [p =.537], day 10 [p =.331], and day 30 [p =.517])
PMID 36806734 · one of two readings recorded this
FTM Part C (functional disability), between-group treatment difference
no effect, p = 0.517, n = 38
functional disability (day 5 [p =.537], day 10 [p =.331], and day 30 [p =.517])
PMID 36806734 · one of two readings recorded this
FTM Part C (functional disability), between-group treatment difference
no effect, p = 0.537, n = 38
functional disability (day 5 [p =.537], day 10 [p =.331], and day 30 [p =.517])
PMID 36806734 · one of two readings recorded this
FTM Part C (functional disability), change from baseline test
no effect, p = 0.301, n = 18
tremor severity (day 5 [p =.641], day 10 [p =.279]), specific motor tasks (day 5 [p =.645], day 10 [p =.128]), functional disability (day 5 [p =.823], day 10 [p =.301]), and FTM Total score (day 5 [p =.669], day 10 [p =.189])
PMID 36806734 · one of two readings recorded this
FTM Part C (functional disability), change from baseline test
decreases, p = 0.026, n = 18
tremor severity (p =.024), specific motor tasks (p =.013), functional disability (p =.026), and FTM total score (p =.012) were significantly reduced compared with baseline
PMID 36806734 · one of two readings recorded this
FTM Part C (functional disability), change from baseline test
no effect, p = 0.823, n = 18
tremor severity (day 5 [p =.641], day 10 [p =.279]), specific motor tasks (day 5 [p =.645], day 10 [p =.128]), functional disability (day 5 [p =.823], day 10 [p =.301]), and FTM Total score (day 5 [p =.669], day 10 [p =.189])
PMID 36806734 · one of two readings recorded this
FTM Part C (functional disability), change from baseline test
no effect, p = 0.061, n = 20
Functional disability did not differ at either time point (day 10 [p =.061], day 30 [p =.060])
PMID 36806734 · one of two readings recorded this
FTM Part C (functional disability), change from baseline test
no effect, p = 0.06, n = 20
Functional disability did not differ at either time point (day 10 [p =.061], day 30 [p =.060])
PMID 36806734 · one of two readings recorded this
FTM Part C (functional disability), change from baseline test
no effect, p = 0.549, n = 20
FTM score Part A, tremor severity (p =.242); FTM score Part B, specific motor tasks (p =.197); FTM score Part C, functional disability (p =.549); and FTM total score (p =.155) on day 5 compared with baseline
PMID 36806734 · one of two readings recorded this
FTM Part C (functional disability), mean ± SD
no effect, n = 18
FTM Part C | 9.83 ± 4.40 | 9.67 ± 4.35 | 8.61 ± 4.06 | 6.66 ± 3.11
PMID 36806734 · one of two readings recorded this
FTM Part C (functional disability), mean ± SD
decreases, n = 18
FTM Part C | 9.83 ± 4.40 | 9.67 ± 4.35 | 8.61 ± 4.06 | 6.66 ± 3.11
PMID 36806734 · one of two readings recorded this
FTM Part C (functional disability), mean ± SD
no effect, n = 18
FTM Part C | 9.83 ± 4.40 | 9.67 ± 4.35 | 8.61 ± 4.06 | 6.66 ± 3.11
PMID 36806734 · one of two readings recorded this
FTM Part C (functional disability), mean ± SD
decreases, n = 20
FTM Part C | 9.75 ± 3.61 | 9.00 ± 3.43 | 7.50 ± 3.40 | 7.50 ± 3.63
PMID 36806734 · one of two readings recorded this
FTM Part C (functional disability), mean ± SD
decreases, n = 20
FTM Part C | 9.75 ± 3.61 | 9.00 ± 3.43 | 7.50 ± 3.40 | 7.50 ± 3.63
PMID 36806734 · one of two readings recorded this
FTM Part C (functional disability), mean ± SD
decreases, n = 20
FTM Part C | 9.75 ± 3.61 | 9.00 ± 3.43 | 7.50 ± 3.40 | 7.50 ± 3.63
PMID 36806734 · one of two readings recorded this
FTM total score, between-group treatment difference
no effect, p = 0.147, n = 38
for the FTM total score, the treatment difference (rTMS effect‐propranolol effect) was not significant on day 5 (p =.198), day 10 (p =.147), or day 30 (p =.639)
PMID 36806734 · one of two readings recorded this
FTM total score, between-group treatment difference
no effect, p = 0.639, n = 38
for the FTM total score, the treatment difference (rTMS effect‐propranolol effect) was not significant on day 5 (p =.198), day 10 (p =.147), or day 30 (p =.639)
PMID 36806734 · one of two readings recorded this
FTM total score, between-group treatment difference
no effect, p = 0.198, n = 38
for the FTM total score, the treatment difference (rTMS effect‐propranolol effect) was not significant on day 5 (p =.198), day 10 (p =.147), or day 30 (p =.639)
PMID 36806734 · one of two readings recorded this
FTM total score, change from baseline test
no effect, p = 0.189, n = 18
tremor severity (day 5 [p =.641], day 10 [p =.279]), specific motor tasks (day 5 [p =.645], day 10 [p =.128]), functional disability (day 5 [p =.823], day 10 [p =.301]), and FTM Total score (day 5 [p =.669], day 10 [p =.189])
PMID 36806734 · one of two readings recorded this
FTM total score, change from baseline test
decreases, p = 0.012, n = 18
tremor severity (p =.024), specific motor tasks (p =.013), functional disability (p =.026), and FTM total score (p =.012) were significantly reduced compared with baseline
PMID 36806734 · one of two readings recorded this
FTM total score, change from baseline test
no effect, p = 0.669, n = 18
tremor severity (day 5 [p =.641], day 10 [p =.279]), specific motor tasks (day 5 [p =.645], day 10 [p =.128]), functional disability (day 5 [p =.823], day 10 [p =.301]), and FTM Total score (day 5 [p =.669], day 10 [p =.189])
PMID 36806734 · one of two readings recorded this
FTM total score, change from baseline test
decreases, p = 0.01, n = 20
tremor severity (p =.006), specific motor tasks (p =.034), and FTM total score (p =.010) were significantly reduced on day 10 after rTMS
PMID 36806734 · one of two readings recorded this
FTM total score, change from baseline test
decreases, p = 0.013, n = 20
persisted until day 30 (tremor severity [p =.011], specific motor tasks [p =.039], and FTM total score [p =.013])
PMID 36806734 · one of two readings recorded this
FTM total score, change from baseline test
no effect, p = 0.155, n = 20
FTM score Part A, tremor severity (p =.242); FTM score Part B, specific motor tasks (p =.197); FTM score Part C, functional disability (p =.549); and FTM total score (p =.155) on day 5 compared with baseline
PMID 36806734 · one of two readings recorded this
FTM total score, mean ± SD
no effect, n = 18
FTM total | 30.61 ± 12.97 | 29.33 ± 12.79 | 25.67 ± 11.14 | 20.16 ± 9.39
PMID 36806734 · one of two readings recorded this
FTM total score, mean ± SD
decreases, n = 18
FTM total | 30.61 ± 12.97 | 29.33 ± 12.79 | 25.67 ± 11.14 | 20.16 ± 9.39
PMID 36806734 · one of two readings recorded this
FTM total score, mean ± SD
no effect, n = 18
FTM total | 30.61 ± 12.97 | 29.33 ± 12.79 | 25.67 ± 11.14 | 20.16 ± 9.39
PMID 36806734 · one of two readings recorded this
FTM total score, mean ± SD
decreases, n = 20
FTM total | 28.65 ± 10.84 | 25.15 ± 9.54 | 20.45 ± 9.01 | 20.80 ± 9.29
PMID 36806734 · one of two readings recorded this
FTM total score, mean ± SD
decreases, n = 20
FTM total | 28.65 ± 10.84 | 25.15 ± 9.54 | 20.45 ± 9.01 | 20.80 ± 9.29
PMID 36806734 · one of two readings recorded this
FTM total score, mean ± SD
decreases, n = 20
FTM total | 28.65 ± 10.84 | 25.15 ± 9.54 | 20.45 ± 9.01 | 20.80 ± 9.29
PMID 36806734 · one of two readings recorded this
APGAR below 7 at 1 min
no effect, n = 128
10 (15.62%) | 9 (14.06%)
PMID 37016326 · one of two readings recorded this
APGAR below 7 at 5 min
no effect, n = 128
1 (1.56%) | 1 (1.56%)
PMID 37016326 · one of two readings recorded this
APGAR score at 1 min
no effect, p = 0.798, n = 128
APGAR score 1 min APGAR below 7 | Mean ± SD | 7.5 ± 0.9 | 7.45 ± 1 | 0.798 NSa
PMID 37016326 · one of two readings recorded this
APGAR score at 5 min
no effect, p = 0.312, n = 128
APGAR score 5 min APGAR below 7 | Mean ± SD | 8.9 ± 0.6 | 8.8 ± 0.6 | 0.312 NSa
PMID 37016326 · one of two readings recorded this
baseline Bishop score
no effect, p = 0.094, n = 128
Bishop score | Mean ± SD | 4.1 ± 1.08 | 3.8 ± 1.2 | 0.094 NSb
PMID 37016326 · one of two readings recorded this
baseline body mass index
no effect, p = 0.141, n = 128
BMI (kg/m 2) | Mean ± SD | 26.4 ± 2.7 | 25.7 ± 2.7 | 0.141 NSa
PMID 37016326 · one of two readings recorded this
baseline gestational age
no effect, p = 0.549, n = 128
G. Age (weeks) | Mean ± SD | 41.04 ± 1.3 | 41.2 ± 1.3 | 0.549* NSa
PMID 37016326 · one of two readings recorded this
baseline maternal age
no effect, p = 0.533, n = 128
Age (years) | Mean ± SD | 23.3 ± 4.1 | 22.9 ± 3.2 | 0.533 NSa
PMID 37016326 · one of two readings recorded this
duration of active phase
no effect, p = 0.425, n = 84
Duration of Active Phase (hours) (45 cases in group I, 39 cases in group II) | Mean ± SD | 3.9 ± 2.7 | 3.5 ± 2.9 | 0.425 NS 3
PMID 37016326 · one of two readings recorded this
duration of latent phase
decreases, p = 0.017, n = 84
Duration of Latent phase (hours) (45 cases in group I, 39 cases in group II) | Mean ± SD | 7.9 ± 5.6 | 9.2 ± 6.03 | 0.017 S 3
PMID 37016326 · one of two readings recorded this
fetal weight
no effect, p = 0.229, n = 128
Fetal weight (kg) | Mean ± SD | 3.45 ± 0.4 | 3.53 ± 0.4 | 0.229 NSa
PMID 37016326 · one of two readings recorded this
indication of cesarean section: failed induction
no effect, n = 44
Failed induction (n %) | 2 | 10.5% | 1 | 4%
PMID 37016326 · one of two readings recorded this
indication of cesarean section: failed progress
no effect, p = 0.713, n = 44
Indication of CS (19 cases in group I, 25 cases in group II) | Failed progress (n %) | 7 | 36.8% | 9 | 36% | 0.713 NS 2
PMID 37016326 · one of two readings recorded this
indication of cesarean section: fetal distress
no effect, n = 44
Fetal distress (n) %) | 10 | 52.6% | 15 | 60%
PMID 37016326 · one of two readings recorded this
indication of induction: GDM
no effect, p = 1, n = 128
GDM (n %) | 1 | 1.6% | 1 | 1.6% | 1.0 NS 2
PMID 37016326 · one of two readings recorded this
indication of induction: HTN
no effect, p = 0.41, n = 128
HTN (n %) | 6 | 9.4% | 9 | 14.1% | 0.41*NS 1
PMID 37016326 · one of two readings recorded this
indication of induction: post date
no effect, p = 0.355, n = 128
Indication of induction | Post date (n %) | 39 | 60.9% | 44 | 68.8% | 0.355 NS 1
PMID 37016326 · one of two readings recorded this
indication of induction: ROM
no effect, p = 0.08, n = 128
ROM (n %) | 18 | 28.1% | 10 | 15.6% | 0.08 NS 1
PMID 37016326 · one of two readings recorded this
induction-delivery interval
decreases, p = 0.027, n = 84
Induction-delivery interval (hours) (45 cases in group I, 39 cases in group II) | Mean ± SD | 11.8 ± 8.1 | 12.6 ± 8.9 | 0.027 S 3
PMID 37016326 · one of two readings recorded this
induction-to-delivery interval in hours after vaginal misoprostol 25 mcg induction of labor in full-term primigravidae, propranolol 20 mg versus placebo (misoprostol in both arms)
decreases, 11.8 +/- 8.1 h vs 12.6 +/- 8.9 h, Group I vs Group II
Not recorded as a finding: a node exists but the paper states a different instrument or population
Table 2 shows a significantly shorter latent phase of labor in Group I when compared to Group II (7.9 ± 5.6 h. vs. 9.2 ± 6.03 h.), as well as a significantly shorter induction-delivery interval (11.8 ± 8.1 h. vs. 12.6 ± 8.9 h.).
PMID 37016326 · one of two readings recorded this
induction-to-delivery interval in hours among primigravidae delivering vaginally (primary), and duration of the latent phase of labor in hours; oral propranolol 20 mg plus vaginal misoprostol versus placebo plus vaginal misoprostol
decreases, 11.8 vs 12.6 h induction-delivery interval; 7.9 vs 9.2 h latent phase, propranolol group versus placebo group
Not recorded as a finding: this platform holds no node for the endpoint
Table 2 shows a significantly shorter latent phase of labor in Group I when compared to Group II (7.9 ± 5.6 h. vs. 9.2 ± 6.03 h.), as well as a significantly shorter induction-delivery interval (11.8 ± 8.1 h. vs. 12.6 ± 8.9 h.).
PMID 37016326 · one of two readings recorded this
misoprostol doses needed: 1 dose
no effect, p = 0.79, n = 84
Misoprostol dose (No. of doses) (45 cases in group I, 39 cases in group II) | 1 dose (n %) | 14 | 31.1% | 14 | 35.9% | 0.79 NS 2
PMID 37016326 · one of two readings recorded this
misoprostol doses needed: 2 doses
no effect, n = 84
2 dose (n %) | 28 | 62.2% | 22 | 56.4%
PMID 37016326 · one of two readings recorded this
misoprostol doses needed: 3 doses
no effect, n = 84
3 dose (n %) | 2 | 4.4% | 2 | 5.1%
PMID 37016326 · one of two readings recorded this